DDIT3 Immunohistochemical expression as a diagnostic marker for Myxoid Liposarcoma

Dr. Jason Hornick discusses his team recent study finding that a monoclonal antibody directed against the N-terminus of DDIT3 is a highly sensitive and specific for high-grade MLPS. DDIT3 immunostains could replace molecular genetic testing in many cases, although limited labeling may be seen in a range of other tumor types. Study by Hornick et al, Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas. Modern Pathology, 34, 1367–1372, 2021

Hosted on Acast. See acast.com/privacy for more information.

More from ModPath Chat

  1. 17:47Morphologic Feature Guiding Discovery of Driver Genetic Alteration in Rare EntityNov 24, 2022
  2. 25:54Risk Stratification for SLNB in MelanomaNov 10, 2022
  3. 29:59Flat urothelial lesions of the urinary bladder: Who is in who is out?Oct 27, 2022
  4. 17:54Radio-Resistant Prostate Carcinoma: “Cribriform” morphologies and DNA Damage Response and Repair defectsOct 13, 2022
  5. 17:58The Stanford Experience in Implementation of the Molecular Classification of Endometrial carcinomas (EC)Sep 29, 2022
  6. 21:19Expanding the clinico-pathological spectrum of SDH Deficient RCCSep 15, 2022
  7. 22:01High Risk and Selected Benign Breast Lesions on Core Biopsy: Excision Vs Surveillance?Sep 01, 2022
  8. 21:31Are ancillary studies of any utility in risk assessment of Barrett’s esophagus and dysplasia?Aug 18, 2022
  9. 17:55Ki-67 assessment in pancreatic neuroendocrine neoplasms manual vs. digital?Aug 04, 2022
  10. 15:21Heterogeneity of molecular alterations in CRC with peritoneal carcinomatosisJul 21, 2022